Clinical expectations for BCR-ABL monitoring have evolved over time both in response to more sensitive tests being developed and new treatments and management approaches emerging. Largely in response to these medical advances, many CML patients have been able to successfully manage their diseases over time, as evidenced through increasing long-term survival rates. Chronic management of an increasing population of CML patients, however, places unique pressure on supporting laboratories, requiring that testing become sensitive enough to support a broad spectrum of clinical decisions while also be scalable to accommodate an ever increasing number of tests.
WATCH THE WEBINAR
In this recorded webinar presentation, learn how the CE-IVD certified QuantideX® qPCR BCR-ABL IS Kit can overcome these challenges, providing a simple, sensitive, and scalable approach to BCR-ABL monitoring that meets and exceeds today’s clinical expectations for testing.
Hosted by Justin T Brown, PhD Principal Scientist of Research and Development at Asuragen, who supply the product, the webinar covers:
- The way in which molecular monitoring fits within CML practice guidelines and how that continues to evolve and add incremental burden to laboratories.
- Key performance data for the QuantideX qPCR BCR-ABLIS kit and how it exceeds monitoring requirements while maintaining operational efficiency.
- Why CML management during the COVID-19 pandemic requires continued monitoring.
Run Time: 56min (incl. Q&A)